Tariq Rizvi, MD
Internal Medicine · Somerset, NJNPI 1447277918
Payments from drug & device makers
Across 537 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Medtronic$1K
- AbbVie$762
- Boston Scientific$689
- Lilly USA, LLC$649
- Boehringer Ingelheim$630
- plus $4K from 35 others
What the payments were for
- Travel & lodging$9169%
- Food & beverage$9,78491%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 132 | $2,803 |
| Medtronic(2 entities) | 8 | $1,053 |
| AbbVie(2 entities) | 57 | $762 |
| Boston Scientific | 20 | $689 |
| Lilly USA, LLC | 42 | $649 |
| Boehringer Ingelheim | 43 | $630 |
| Novo Nordisk | 44 | $572 |
| Johnson & Johnson | 25 | $360 |
| Shockwave Medical, Inc | 2 | $288 |
| Pfizer | 18 | $253 |
| Exact Sciences | 12 | $230 |
| GSK | 15 | $226 |
| Abbott | 10 | $212 |
| Novartis | 10 | $197 |
| Kestra Medical Technology Services, Inc. | 1 | $178 |
| Bayer | 7 | $160 |
| Merck | 11 | $158 |
| Eisai Inc. | 8 | $140 |
| Amgen | 9 | $134 |
| Kowa Pharmaceuticals America, Inc. | 9 | $130 |
| Corcept Therapeutics | 6 | $115 |
| Daiichi Sankyo Inc. | 7 | $106 |
| Astellas Pharma US Inc | 7 | $94 |
| Mannkind Corporation | 6 | $84 |
| Abiomed | 1 | $80 |
| Sanofi Pasteur Inc. | 4 | $53 |
| Bausch Health US, LLC | 3 | $45 |
| Amarin Pharma, Inc. | 3 | $43 |
| Antares Pharma, Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Nevro Corp. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Baxter Healthcare | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Corium, LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Watermark Medical, Inc. | 1 | $13 |
| IBSA Pharma Inc. | 1 | $12 |
| Acarix USA Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$916
- FARXIGA$310
- BREZTRI$310
- TEZSPIRE$292
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$288
- AIRSUPRA$181
- Assure WCD$178
- ELUVIA$145
How this compares
$10,705 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 132 | $173,215 |
| MounjaroTirzepatide | 79 | $98,771 |
| EliquisApixaban | 69 | $92,833 |
| FarxigaDapagliflozin Propanediol | 49 | $63,531 |
| JanuviaSitagliptin Phosphate | 37 | $53,727 |
| JanumetSitagliptin Phos/Metformin Hcl | 44 | $45,798 |
| JardianceEmpagliflozin | 37 | $44,203 |
| XareltoRivaroxaban | 29 | $31,686 |
| ProliaDenosumab | 17 | $29,126 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $14,301 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $10,368 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,385 |
| PentasaMesalamine | 12 | $7,971 |
| Rosuvastatin Calcium | 534 | $7,664 |
| Atorvastatin Calcium | 651 | $7,337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $572 | $173,215132 claims |
| MerckJanuvia, Janumet, Janumet Xr | $158 | $109,89298 claims |
| Lilly USA, LLCMounjaro | $649 | $98,77179 claims |
| PfizerEliquis | $253 | $92,83369 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Nexium | $2,803 | $80,74174 claims |
| Boehringer IngelheimJardiance | $630 | $44,20337 claims |
| Johnson & JohnsonXarelto | $360 | $31,68629 claims |
| AmgenProlia | $134 | $29,12617 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $226 | $12,41623 claims |
| AbbVieSynthroid | $762 | $4,82384 claims |
| Esperion Therapeutics, Inc.Nexletol | $31 | $4,35311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Somerset
- Devraj LahiriSomerset$695K
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.